Literature DB >> 15914962

Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy.

Seok-Gu Kang1, Jong Hyun Kim, Do Hyun Nam, Kwan Park.   

Abstract

The clinical and radiological prognostic factors were investigated in 32 patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy using surgery, postoperative radiation therapy, and adjuvant chemotherapy between September 1994 and December 2002. Surgery aimed at total removal was followed by radiotherapy, and 3 weeks later by adjuvant chemotherapy repeated at 6- to 7-week intervals. Survival analysis showed that younger age, absence of preoperative headache, good postoperative Karnofsky Performance Status (KPS) score (>or=80), and relatively small tumor volume (<50 cm3) were predictors for longer survival in univariate analysis (p<0.05). Age and good postoperative KPS score were independent prognostic factors in multivariate analysis (p<0.05). Median survival was 58 months after diagnosis, and the 5-year survival rate was 49%.

Entities:  

Mesh:

Year:  2005        PMID: 15914962     DOI: 10.2176/nmc.45.232

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  9 in total

1.  Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.

Authors:  Giampiero Ausili Céfaro; Domenico Genovesi; Annamaria Vinciguerra; Marianna Trignani; Maria Taraborrelli; Antonietta Augurio; Roberto Buonaguidi; Renato J Galzio; Marta Di Nicola
Journal:  Strahlenther Onkol       Date:  2011-11-25       Impact factor: 3.621

2.  Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo through the Bcl-2/caspase pathways.

Authors:  Hongliang Jiao; Fangxia Guan; Bo Yang; Jianbin Li; Laijun Song; Xiang Hu; Ying Du
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

3.  Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors:  Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  J Neurooncol       Date:  2013-03-13       Impact factor: 4.130

4.  Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells.

Authors:  Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Seong Muk Kim; Yoon Sun Yang; Won Il Oh; Pil-Woo Huh; Chun Kun Park
Journal:  Childs Nerv Syst       Date:  2007-10-30       Impact factor: 1.475

5.  Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (DKK1).

Authors:  Shanshan Ma; Shuo Liang; Hongliang Jiao; Liankai Chi; Xinyi Shi; Yi Tian; Bo Yang; Fangxia Guan
Journal:  Mol Cell Biochem       Date:  2013-10-09       Impact factor: 3.396

6.  Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Andrew J Tsung; Christopher S Gondi; Jeffrey D Klopfenstein; Sanjeeva Mohanam; Jasti S Rao
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

7.  Prognostic factors associated with survival in patients with anaplastic oligodendroglioma.

Authors:  Shuo Liu; Xiaoqiang Liu; Yingxiu Xiao; Shuying Chen; Weiduan Zhuang
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

8.  Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas.

Authors:  Qiaoshu Wang; Zhaoyun Zhang; Tianling Ding; Zi Chen; Tao Zhang
Journal:  Biosci Rep       Date:  2013-02-01       Impact factor: 3.840

9.  Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling.

Authors:  Ho Kang; Jongjin Lee; So Young Ji; Seung Won Choi; Kyung-Min Kim; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Kyung-Sub Moon; Chae-Yong Kim; Heon Yoo; Do-Hyun Nam; Jeong Hoon Kim; Yongdai Kim; Chul-Kee Park
Journal:  Neurooncol Adv       Date:  2021-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.